Stoke Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Stoke Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $465.00K, a 25.68% increase year-over-year.
- Stoke Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $632.00K, a 73.63% increase year-over-year.
- Stoke Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $370.00K, a 120.24% increase year-over-year.
- Stoke Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $364.00K, a 9.23% decline year-over-year.
- Stoke Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $1.00M, a 88.35% increase from fiscal 2024.
- Stoke Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $532.00K, a 4.14% decline from fiscal 2023.
- Stoke Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $555.00K, a 2.63% decline from fiscal 2022.
- Stoke Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $570.00K, a 11.98% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-03-31 | $465.00K 10-Q · filed 2026-08-03 | |
| 2025-12-31 | $1.00M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $632.00K 10-Q · filed 2025-11-04 | |
| 2025-03-31 | $370.00K 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $532.00K 10-K · filed 2026-03-16 | |
| 2024-09-30 | $364.00K 10-Q · filed 2025-11-04 | |
| 2024-03-31 | $168.00K 10-Q · filed 2025-11-04 | |
| 2023-12-31 | $555.00K 10-K · filed 2025-03-18 | |
| 2023-09-30 | $401.00K 10-Q · filed 2024-11-05 | |
| 2023-03-31 | $153.00K 10-Q · filed 2024-11-05 | |
| 2022-12-31 | $570.00K 10-K · filed 2024-03-25 | |
| 2022-09-30 | $401.00K 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $169.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $509.00K 10-K · filed 2023-03-06 | |
| 2021-09-30 | $334.00K 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $175.00K 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $352.00K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $352.00K 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |